MDR Enterococci- Race for Supremacy between Enterococci and Antibiotics

Title: MDR Enterococci- Race for Supremacy between Enterococci and Antibiotics

Authors: Dr Jyoti P. Sonawane, Dr Rita Swaminathan, Dr Nadeem A.L. Ameen

DOI: https://dx.doi.org/10.18535/jmscr/v5i2.129

Abstract

Introduction: Enterococci, considered a normal commensal of intestinal tract, are fast emerging as a pathogen causing serious and life threatening hospital borne infections. During the last few years, enterococci have acquired resistance to a number of important antibiotics like Penicillin, Aminoglycosides including glycopeptides which pose a serious challenge not only for clinicians but also for health care institutions. It results in treatment failure, selection and spreading of resistant strains in the health care institution.

Aims & Objective: In view of this, the present study was undertaken to know the prevalence of multi drug resistant Enterococcus Species with special reference to Vancomycin.

Materials & Methods: During the study period of 6 months from January 2015 to June 2015, from 3131 clinical samples received by Microbiological laboratory, 207(6.61%) Enterococci were isolated and identified by using standard microbiological techniques and their antimicrobial susceptibility was performed according to CLSI guidelines. E-test was performed on Vancomycin resistant strains to detect the MIC of Vancomycin.

Results: Out of 3131 samples, 207(6.61%) samples were positive for Enterococcal species. of which 123 (59.42%) isolates were E.faecalis, 55(26.57%) E.faecium, & 29 (14.01%) other Enterococcus Spp. Maximum isolation was from Urine 143(69.08%) followed by Pus 43(20.77%) and 08(3.86%) broncho-alveolar lavage samples. 102 (49.28%) isolates were multidrug resistant Enterococci. Of which 52(50.98%) were MDR E.faecium and 50 (49.02%) MDR E.faecalis. Two isolates, both urine samples and Vancomycin resistant (VRE), were Entercoccus faecium. They showed (100%) sensitive to Linezolid, (99.03%) sensitivity to Vancomycin. Other resistant drugs in our study were Nitrofurantoin (60.84% used only in urinary isolates), Amikacin (74.40%), Gentamicin(74.88%), Ciprofloxacin (78.74%), Erythromycin (82.61%) and Penicillin (93.72%).

Conclusion: Empirical therapy for Enterococcal infections should be guided by local patterns of drug resistance. Regular screening of Enterococcal isolates for Vancomycin resistance detection should be implemented along with the infection control measures, screening of health care workers and surveillance of cultures which can control spread of multidrug resistant Enterococci.

Keywords: Enterococci, Multidrug resistant (MDR), E-Test, Vancomycin.

References

1. Gilmore MS; et al., eds. (2002). The Enter-ococci: Pathogenesis, Molecular Biology, and Antibiotic Resistance. Washington, D.C.: ASM Press. ISBN 978-1-55581-234-8.

2. Koneman’s Color Atlas and Textbook of Diagnostic Microbiology, Sixth Edition, p700-701.

3. Giridhara Upadhyaya PM, Ravikumar KL, Umapathy BL. Review of virulence factor of enterococcus: An Emerging nosocomial pathogen. Indian J Med Microbiol 2009; 27:301-5.

4. Schouten MA, Hoogkamp-Korstanje JA, Meis JF, Voss A. Prevalence of vancomycin resistant enterococci in Europe. Eur J Clin Microbiol Infect Dis 2000; 19:816-22.

5. Schaberg DR, Culver DH, Gaynes RP. Major trends in microbial aetiology of nosocomial infection. Am J Med 1991; 91:72s-5s.

6. [Sava, G., Heikens, E. and Huebner, J. (2010) Pathogenesis and Immunity in Enterococcal Infections. Clinical Microbi- ology and Infection, 16, 533-540. http://dx.doi.org/10.1111/j.1469-0691.2010.03213.x]

7. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev. 1990; 3:46-65.

8. Moellering Jr RC. Emergence of Enterococcus as a significant pathogen. Clin Infect Dis. 1992; 14:1173-1178.

9. Ike Y, Hashimoto H, Clewell DB. Haemolysin of Streptococcus faecalis subspecies zymogenes contributes to virulence in mice. Infect Immun 1984; 45:528-30

10. Udo EE, Al-Sweih N, Phillips OA, Chugh TD. Species prevalence and antibacterial resistance of enterococci isolated in Kuwait hospitals. J Med Microbiol 2003; 52:163-8.

11. [Mohanty, S., Dhawan, B., Gadepalli, R.S., Lodha, R. and Kapil, A. (2006) Case Report of Vancomycin Resistant En- terococcus Faecium VanA Phenotype: First Documented Isolation in India. The Southeast Asian Journal of Tropical Medicine and Public Health, 37, 335-337.]

12. [Gangurde,N., Mane, M. and Phatale, S. (2014) Prevalence of Multidrug Resistant Enterococci in a Tertiary Care Hospital in India: A Growing Threat. Open Journal of Medical Microbiology, 4, 11-15. http://dx.doi.org/10.4236/ojmm.2014.41002].

13. [Collee, J.G., Fraser, A.G., Marmion, B.P. and Simmons, A. (2008) Chapter 7: Test for Identification of Bacteria. In: Collee, J.G., Miles, R.S. and Watt, B., Eds., Test for Identification of Bacteria, Mackie & McCartney’s Practical Medical Microbi-ology, 14th Edition, Indian Reprint, Churchil Livingstone, 131-149.]

14. [Forbes, A.B., Sahm, D.F. and Weissfeld, A.S. (2007) Chapter 13: Overview of Bacterial Identification Methods and Strategies. In: Baily & Scott’s Diagnostic Microbiology 12th Ed., Mosby Elsevier International Edition, 216-247.

15. [Wayne, P.A. (2010) Clinical & Labor-atory Standard Institute, Performance Standard for Antimicrobial Susceptibility Testing. Twentieth Informational Supplement, 30, M100-M120.]

16. Rahangdale V A, Agrawal G, Jalgaonkar S V. Study of antimicrobial resistance in enterococci. Indian J Med Microbiol 2008; 26:285-7.

17. M M Salem-Bekhit, Prevalence and antimicrobial resistance pattern of multidrug-resistant enterococci isolated from clinical specimens, Indian Journal of Medical Microbiology Year : 2012 | Volume : 30 | Issue : 1 | Page : 44-51.

18. Maj. Puneet Bhatt, Anubha Patel, Brig A.K. Sahni, Surg Cmde A.K. Praharaj, (Retd), Col Naveen Grover, Surg Cdr C.N. Chaudhari, Nikunja Kumar Das, Mayuri Kulkarni, Emergence of multidrug resistant Enterococci at a tertiary care centre, Medical Journal Armed Forces India 71(2015) 139-144.

19. De A, Bindlish A, Kumar S, Mathur M. Vancomycin resistant enterococci in a tertiary care hospital in Mumbai. Indian J Med Microbiol 2009; 27:375-6.

20. Mathur P, Kapil A, Chandra R, Sharma P, Das B. Antimicrobial resistance in Enterococcus faecalis at a tertiary care centre in Northern India. Indian J Med Res. 2003; 118:25-28.

21. Karmarkar MG, Gershom ES, Mehta PR. Enterococcal infections with special reference to phenotypic characterization & drug resistance. Indian J Med Res.2004; 119(suppl l):22-25.

22. Kapoor L, Randhawa VS, Deb M. Antimicrobial resistance of Enterococcal blood isolates at a pediatric care hospital in India. Jpn J Infect Dis. 2005; 58(2):101-103.

23. Deshpande VR, Karmarkar MG, Mehta PR. Prevalence of multidrug resistant Enterococci in a tertiary care hospital in Mumbai, India. J Infect Dev Ctries. 2013; 7(2):155-158.

24. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant Enterococci. Clin Microbiol Rev. 2000; 13:686-707.

25. Murray BE. Vancomycin-resistant Enterococcal infections. N Engl J Med. 2000; 342:710-721.

26. Bose, S., Ghosh, A. and Barapatre, R. (2012) Prevalence of Drug Resistance among Enterococcus Species Isolated from A Tertiary Care Hospital. International Journal of Medical Health Sciences, 1, 38-44.

27. Fernandes, S.C., Dhanashree, B., et al. (2013) Drug Resistance & Virulence Determinants in Clinical Isolates of Ente- rococcus Species. Indian Journal of Medical Research, 137, 981-985.

28. Telkar, A., et al. (2012) Change in the Prevalence and the Antibiotic Resistance of the Enterococcal Species Isolated from Blood Culture. Journal of Clinical and Diagnostic Research, 6, 405-407.

29. Jain, S., Kumar, A., Kashyap, B. and Kaur, I.R. (2011) Clinico-Epidemiological Profile and High-Level Aminoglyco- side Resistance in Enterococcal Septicemia from a Tertiary Care Hospital in East Delhi. International Journal of Ap- plied and Basic Medical Research, 1, 80-83. http://dx.doi.org/10.4103/2229-516X.91149

30. Huycke, M.M., Sahm, D.F. and Gilmore, M.S. (1998) Multiple-Drug Resistant Enterococci: The Nature of the Problem and an Agenda for the Future. Emerging Infectious Diseases, 4, 239-249. http://dx.doi.org/10.3201/eid0402.980211.

Abstract

References

Corresponding Author

Call For Paper Volume 12 Issue 10 November 2024

JMSCR Menu

Impact Factor SJIF 2024: 7.892

Crossref - DOI

Editorial Policy

Frequency of Publication

Submission of Articles

Search

Abstract

Call For Paper Volume 12 Issue 10 November 2024

JMSCR Menu

Impact Factor SJIF 2024: 7.892

Crossref - DOI

Editorial Policy

Frequency of Publication

Submission of Articles